Skip to main content

Pyxis Oncology, Inc 8-K, filed Nov 5, 2026

Pyxis Oncology, Inc. (PYXS)

8-K 2026-11-05 For: 2026-11-05
View Original
Added on November 05, 2026

About this 8-K

Pyxis Oncology, Inc filed this 8-K on November 5, 2026.

Pyxis Oncology reported a 36% confirmed objective response rate (12/33) for MICVO and plans to initiate the global Phase 3 HeadlinerSM trial in mid-2027. Cash plus net offering proceeds is expected to fund operations into the first half of 2028. AI summary

Items reported

  • Item 2.02: Financial results